Rodrigo A Ledezma1, Edris Negron2, Gladell P Paner3, Chris Rjepaj4, Danny Lascano5, Mohammed Haseebuddin6, Pankaj Dangle2, Arieh L Shalhav2, Henry Crist7, Jay D Raman4, G Joel DeCastro5, Lara Harik8, Monika Paroder8, Robert G Uzzo6, Alexander Kutikov6, Scott E Eggener2. 1. Section of Urology, Department of Surgery, University of Chicago Medical Center, 5841 South Maryland Avenue, MC6038, J-664, Chicago, IL, 60637, USA. rodrigoledezma@gmail.com. 2. Section of Urology, Department of Surgery, University of Chicago Medical Center, 5841 South Maryland Avenue, MC6038, J-664, Chicago, IL, 60637, USA. 3. Department of Pathology, University of Chicago Medical Center, Chicago, IL, USA. 4. Division of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA. 5. Department of Urology, Columbia University, New York, NY, USA. 6. Division of Urologic Oncology, Fox Chase Cancer Center Temple University Health System, Philadelphia, PA, USA. 7. Department of Pathology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA. 8. Department of Pathology, Columbia University, New York, NY, USA.
Abstract
PURPOSE: We aimed to determine incidence, pathologic findings, prognostic factors and clinical outcomes for patients with clinically localized papillary RCC. METHODS: Demographic, clinical and pathologic findings were collected on all patients with PRCC undergoing surgery at four academic medical centers. The primary endpoint was cancer-specific survival (CSS). Relapse-free survival (RFS) and overall survival (OS) were secondary endpoints. Kaplan-Meier estimates were obtained, and Cox proportional hazard regression models were used to assess predictors of mortality and relapse. RESULTS: We identified 626 PRCC, of which 373 (60 %) were type 1 and 253 (40 %) were type 2, with three-quarters of all tumors being pT1. Compared to patients with type 1, those with type 2 were older (mean age: 63 vs 61; p = 0.02), presented more commonly with symptoms (13 vs 7 %; p = 0.02) and had larger mean tumor size (5.2 vs 4.3 cm; p = 0.001). With a median follow-up of 41 months (IQR: 16-68), 92 patients had died of PRCC (15 %), 48 (8 %) experienced relapse, and 101 died from all causes (16 %). The estimated 5-year CSS, RFS and OS were 83, 91 and 82 %, respectively. In multivariable analysis, older age, T stage and nodal status were predictors of CSS and OS. However, PRCC subtype was not a predictor of CSS, RFS or OS. CONCLUSION: While patients with type 2 PRCC appear to present with more advanced disease than patients with type 1, PRCC subtype does not appear to be an independent predictor of CSS, RFS or OS for treated localized disease.
PURPOSE: We aimed to determine incidence, pathologic findings, prognostic factors and clinical outcomes for patients with clinically localized papillary RCC. METHODS: Demographic, clinical and pathologic findings were collected on all patients with PRCC undergoing surgery at four academic medical centers. The primary endpoint was cancer-specific survival (CSS). Relapse-free survival (RFS) and overall survival (OS) were secondary endpoints. Kaplan-Meier estimates were obtained, and Cox proportional hazard regression models were used to assess predictors of mortality and relapse. RESULTS: We identified 626 PRCC, of which 373 (60 %) were type 1 and 253 (40 %) were type 2, with three-quarters of all tumors being pT1. Compared to patients with type 1, those with type 2 were older (mean age: 63 vs 61; p = 0.02), presented more commonly with symptoms (13 vs 7 %; p = 0.02) and had larger mean tumor size (5.2 vs 4.3 cm; p = 0.001). With a median follow-up of 41 months (IQR: 16-68), 92 patients had died of PRCC (15 %), 48 (8 %) experienced relapse, and 101 died from all causes (16 %). The estimated 5-year CSS, RFS and OS were 83, 91 and 82 %, respectively. In multivariable analysis, older age, T stage and nodal status were predictors of CSS and OS. However, PRCC subtype was not a predictor of CSS, RFS or OS. CONCLUSION: While patients with type 2 PRCC appear to present with more advanced disease than patients with type 1, PRCC subtype does not appear to be an independent predictor of CSS, RFS or OS for treated localized disease.
Authors: John R Srigley; Brett Delahunt; John N Eble; Lars Egevad; Jonathan I Epstein; David Grignon; Ondrej Hes; Holger Moch; Rodolfo Montironi; Satish K Tickoo; Ming Zhou; Pedram Argani Journal: Am J Surg Pathol Date: 2013-10 Impact factor: 6.394
Authors: Ximing J Yang; Min-Han Tan; Hyung L Kim; Jonathon A Ditlev; Mark W Betten; Carolina E Png; Eric J Kort; Kunihiko Futami; Kyle A Furge; Masayuki Takahashi; Hiro-Omi Kanayama; Puay Hoon Tan; Bin Sing Teh; Chunyan Luan; Kim Wang; Michael Pins; Maria Tretiakova; John Anema; Richard Kahnoski; Theresa Nicol; Walter Stadler; Nicholas G Vogelzang; Robert Amato; David Seligson; Robert Figlin; Arie Belldegrun; Craig G Rogers; Bin Tean Teh Journal: Cancer Res Date: 2005-07-01 Impact factor: 12.701
Authors: William R Sukov; Christine M Lohse; Bradley C Leibovich; R Houston Thompson; John C Cheville Journal: J Urol Date: 2011-11-16 Impact factor: 7.450
Authors: Kirk A Keegan; Clayton W Schupp; Karim Chamie; Nicholas J Hellenthal; Christopher P Evans; Theresa M Koppie Journal: J Urol Date: 2012-06-13 Impact factor: 7.450
Authors: Giuseppe Rosiello; Carlotta Palumbo; Sophie Knipper; Angela Pecoraro; Stefano Luzzago; Pierre-Antoine St-Hilaire; Zhe Tian; Umberto Capitanio; Francesco Montorsi; Shahrokh F Shariat; Fred Saad; Alberto Briganti; Pierre I Karakiewicz Journal: World J Urol Date: 2020-04-06 Impact factor: 4.226
Authors: Tobias Klatte; Kevin M Gallagher; Luca Afferi; Alessandro Volpe; Nils Kroeger; Silvia Ribback; Alan McNeill; Antony C P Riddick; James N Armitage; Tevita F 'Aho; Tim Eisen; Kate Fife; Axel Bex; Allan J Pantuck; Grant D Stewart Journal: BMC Med Date: 2019-10-03 Impact factor: 8.775